These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 27070379)

  • 21. Effect of icosapent ethyl on progression of coronary atherosclerosis in patients with elevated triglycerides on statin therapy: a prospective, placebo-controlled randomized trial (EVAPORATE): interim results.
    Budoff MJ; Muhlestein JB; Bhatt DL; Le Pa VT; May HT; Shaikh K; Shekar C; Kinninger A; Lakshmanan S; Roy SK; Tayek J; Nelson JR
    Cardiovasc Res; 2021 Mar; 117(4):1070-1077. PubMed ID: 32609331
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Icosapent ethyl for treatment of elevated triglyceride levels.
    Nelson SD; Munger MA
    Ann Pharmacother; 2013 Nov; 47(11):1517-23. PubMed ID: 24259598
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Switching from EPA + DHA (Omega-3-acid Ethyl Esters) to High-Purity EPA (Icosapent Ethyl) in a Statin-Treated Patient with Persistent Dyslipidemia and High Cardiovascular Risk: A Case Study.
    Crandell JR
    Clin Med Insights Cardiol; 2016; 10():123-8. PubMed ID: 27478390
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical trials of eicosapentaenoic acid (EPA) prescription products for the treatment of hypertriglyceridemia.
    Doggrell SA
    Expert Opin Pharmacother; 2019 Jul; 20(10):1221-1225. PubMed ID: 31038369
    [No Abstract]   [Full Text] [Related]  

  • 25. Icosapent ethyl, a pure EPA omega-3 fatty acid: effects on lipoprotein particle concentration and size in patients with very high triglyceride levels (the MARINE study).
    Bays HE; Braeckman RA; Ballantyne CM; Kastelein JJ; Otvos JD; Stirtan WG; Soni PN
    J Clin Lipidol; 2012; 6(6):565-72. PubMed ID: 23312052
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effectiveness of combined statin plus omega-3 fatty acid therapy for mixed dyslipidemia.
    Barter P; Ginsberg HN
    Am J Cardiol; 2008 Oct; 102(8):1040-5. PubMed ID: 18929706
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Icosapent ethyl: drug profile and evidence of reduced residual cardiovascular risk in patients with statin-managed LDL-C cholesterol.
    Bazarbashi N; Miller M
    Expert Rev Cardiovasc Ther; 2020 Apr; 18(4):175-180. PubMed ID: 32228246
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Icosapent ethyl for the treatment of hypertriglyceridemia.
    Ballantyne CM; Braeckman RA; Soni PN
    Expert Opin Pharmacother; 2013 Jul; 14(10):1409-16. PubMed ID: 23701295
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A retrospective case series of the lipid effects of switching from omega-3 fatty acid ethyl esters to icosapent ethyl in hyperlipidemic patients.
    Castaldo RS
    Postgrad Med; 2014 May; 126(3):268-73. PubMed ID: 24977343
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Understanding why REDUCE-IT was positive - Mechanistic overview of eicosapentaenoic acid.
    Harris WS
    Prog Cardiovasc Dis; 2019; 62(5):401-405. PubMed ID: 31666183
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy and safety of eicosapentaenoic acid ethyl ester (AMR101) therapy in statin-treated patients with persistent high triglycerides (from the ANCHOR study).
    Ballantyne CM; Bays HE; Kastelein JJ; Stein E; Isaacsohn JL; Braeckman RA; Soni PN
    Am J Cardiol; 2012 Oct; 110(7):984-92. PubMed ID: 22819432
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of icosapent ethyl according to baseline residual risk in patients with atherosclerotic cardiovascular disease: results from REDUCE-IT.
    Burger PM; Bhatt DL; Dorresteijn JAN; Koudstaal S; Mosterd A; Martens FMAC; Steg PG; Visseren FLJ;
    Eur Heart J Cardiovasc Pharmacother; 2024 Oct; 10(6):488-499. PubMed ID: 38678009
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Reducing Cardiovascular Disease Risk in Women Beyond Statin Therapy: New Insights 2020.
    Mosca L; Navar AM; Wenger NK
    J Womens Health (Larchmt); 2020 Aug; 29(8):1091-1100. PubMed ID: 32297837
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Catch of the Day: Icosapent Ethyl for Reducing Cardiovascular Risk.
    Dixon DL
    Am J Med; 2020 Jul; 133(7):802-804. PubMed ID: 32243872
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of Icosapent Ethyl on Total Ischemic Events: From REDUCE-IT.
    Bhatt DL; Steg PG; Miller M; Brinton EA; Jacobson TA; Ketchum SB; Doyle RT; Juliano RA; Jiao L; Granowitz C; Tardif JC; Gregson J; Pocock SJ; Ballantyne CM;
    J Am Coll Cardiol; 2019 Jun; 73(22):2791-2802. PubMed ID: 30898607
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Fish oil supplementation attenuates changes in plasma lipids caused by dexamethasone treatment in rats.
    Barbosa AM; Francisco Pde C; Motta K; Chagas TR; Dos Santos C; Rafacho A; Nunes EA
    Appl Physiol Nutr Metab; 2016 Apr; 41(4):382-90. PubMed ID: 26939043
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Potential benefits of icosapent ethyl on the lipid profile: case studies.
    Hilleman DE; Malesker MA
    Clin Med Insights Cardiol; 2014; 8():13-5. PubMed ID: 24516343
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Can pleiotropic effects of eicosapentaenoic acid (EPA) impact residual cardiovascular risk?
    Nelson JR; True WS; Le V; Mason RP
    Postgrad Med; 2017 Nov; 129(8):822-827. PubMed ID: 28974128
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Spotlight on Icosapent Ethyl for Cardiovascular Risk Reduction: Evidence to Date.
    Jia X; Koh S; Al Rifai M; Blumenthal RS; Virani SS
    Vasc Health Risk Manag; 2020; 16():1-10. PubMed ID: 32021223
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A novel, multi-ingredient supplement to manage elevated blood lipids in patients with no evidence of cardiovascular disease: a pilot study.
    Hobbs T; Caso R; McMahon D; Nymark M
    Altern Ther Health Med; 2014; 20(5):18-23. PubMed ID: 25141367
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.